Could a new combo let some cancer patients skip harsh chemo?
NCT ID NCT07177443
First seen Oct 31, 2025 · Last updated May 13, 2026 · Updated 24 times
Summary
This study tests whether a new drug called serplulimab, given with standard induction chemotherapy, can replace the usual concurrent chemotherapy for people with advanced nasopharyngeal cancer. The goal is to see if this approach works as well or better while reducing side effects. About 456 adults aged 18-65 with untreated, advanced nasopharyngeal cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Union Hospital
Wuhan, Hubei, 430022, China
Conditions
Explore the condition pages connected to this study.